Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen

European Journal of Contraception and Reproductive Health Care

Volumn 16, Issue 6, 2011, Pages 430-443

  Mansour, Diana ^a   Verhoeven, Carole ^b   Sommer, Werner ^b   Weisberg, Edith ^c   Taneepanichskul, Surasak ^d   Melis, Gian Benedetto ^e   Sundström Poromaa, Inger ^f   Korver, Tjeerd ^b  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Sydney Centre for Reproductive Health Research   (Australia)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

17 oestradiol; Combined oral contraceptive; Cycle control; Efficacy; Nomegestrol acetate; Safety

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL PLUS NOMEGESTROL ACETATE;

ACNE; ADULT; AMENORRHEA; BLOOD PRESSURE MEASUREMENT; BREAKTHROUGH BLEEDING; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; MENORRHAGIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; OPEN STUDY; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PEARL INDEX; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SPOTTING; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VAGINA BLEEDING; WEIGHT GAIN; WITHDRAWAL BLEEDING;

ACNE VULGARIS; ADOLESCENT; ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; ESTRADIOL; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MEGESTROL; MENSTRUAL CYCLE; METRORRHAGIA; MIDDLE AGED; NORPREGNADIENES; PREGNANCY; PREGNANCY RATE; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 80955140386     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2011.614029     Document Type: Conference Paper

References (47)

1. UN Department of Economic and Social Affairs Population Division. World Contraceptive Use. Accessed 11 June 2010 from: http://www.un.org/esa/population/ publications/contraceptive2009/contraceptive2009. htm.
2. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: A randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 999;60:321-9.
3. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54. (Pubitemid 46551071)
4. Cerel-Suhl SL, Yeager BF. Update on oral contraceptive pills. Am Fam Physician 1999;60:2073-84.
5. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-78. (Pubitemid 43231449)
6. Klipping C, Duijkers I, Trummer D, et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008;78:16-25.
7. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007;75:16-22. (Pubitemid 44854856)
8. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54:71-7. (Pubitemid 26256707)
9. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001;184:255-63. (Pubitemid 32208274)
10. Calafi Alsina J. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. Eur J Contracept Reprod Health Care 2010;15:1-3.
11. Hoffmann H, Moore C, Zimmermann H, et al. Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol 1998;50:458-64.
12. Koetsawang S, Mandlekar AV, Krishna UR, et al. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. Contraception 1980;21:445-59. (Pubitemid 10068906)
13. Wenzl R, Bennink HC, van Beek A, et al. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril 1993; 60:616-9. (Pubitemid 23298503)
14. Hirvonen E, Allonen H, Anttila M, et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas 1995;21:27-32.
15. Kuhl H. Pharmacology of estrogens and progestogens: Infl uence of different routes of administration. Climacteric 2005;8(Suppl. 1):3-63. (Pubitemid 41232429)
16. Sitruk-Ware R. Pharmacological profi le of progestins. Maturitas 2004;47:277-83.
17. Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995;55: 239-46.
18. Lello S. Nomegestrol acetate: Pharmacology, safety profi le and therapeutic efficacy. Drugs 2010;70:541-59.
19. Duijkers I KC, Grob P, Korver T. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 ß -oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. Eur J Contracept Reprod Health Care 2010;15: 314-25.
20. Committee for medicinal products for human use (CHMP). Guideline on clinical investigation of steroid contraceptives in women. Accessed 18 May 2011 from: http://www.ema.europa.eu/docs/en-GB/document- library/Scientifi c-guideline/2009/09/WC500003349. pdf.
21. Benda N, Gerlinger C, van der Meulen EA, et al. Sample size calculation for clinical studies on the efficacy of a new contraceptive method. Biom J 2004;46:141-50. (Pubitemid 41448950)
22. Gerlinger C, Endrikat J, van der Meulen EA, et al. Recommendation for confi dence interval and sample size calculation for the Pearl Index. Eur J Contracept Reprod Health Care 2003;8:87-92. (Pubitemid 36791750)
23. Belsey EM, Farley TM. The analysis of menstrual bleeding patterns: A review. Contraception 1988;38:129-56.
24. Belsey EM, Machin D, d' Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1986; 34:253-60. (Pubitemid 17177017)
25. Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006;74:451-7. (Pubitemid 46043314)
26. Dinger J. Comparative effectiveness of combined oral contraceptives in adolescents. J Fam Plann Reprod Health Care 2011;37:118.
27. Christin-Maitre S, Serfaty D, Chabbert-Buffet N, et al. Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17{beta}-estradiol (NOMAC/E2): A double- blind, randomized study. Hum Reprod 2011;26: 1338-47.
28. Dinger J, Minh TD, Buttmann N, et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011;117: 33-40.
29. Mueck AO, Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011;76:531-9.
30. Ezan E, Benech H, Bucourt R, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993;46:507-14. (Pubitemid 23312322)
31. Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: A seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 2009;80:436-44.
32. Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3 mg-ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150mcg-ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception 2009;80:445-51.
33. Read CM. New regimens with combined oral contraceptive pills-moving away from traditional 21/7 cycles. Eur J Contracept Reprod Health Care 2010;15(Suppl. 2):S32-41.
34. Endrikat JS, Milchev NP, Kapamadzija A, et al. Bleeding pattern, tolerance and patient satisfaction with a drospirenone- containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception 2009;79:428-32.
35. Johannes CB, Crawford SL, Woods J, et al. An electronic menstrual cycle calendar: Comparison of data quality with a paper version. Menopause 2000;7:200-8. (Pubitemid 30249902)
36. Mishell DR, Jr., Guillebaud J, Westhoff C, et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception 2007;75:11-5. (Pubitemid 44854860)
37. Mishell DR, Jr., Guillebaud J, Westhoff C, et al. Combined hormonal contraceptive trials: Variable data collection and bleeding assessment methodologies infl uence study outcomes and physician perception. Contraception 2007;75:4-10. (Pubitemid 44854862)
38. Maloney JM, Dietze P, Jr., Watson D, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008;112:773-81.
39. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, doubleblind, placebo-controlled trial. Contraception 2008; 77:249-56.
40. Coney P, Washenik K, Langley RG, et al Weight change and adverse event incidence with a low-dose oralcontraceptive: Two randomized, placebo-controlled trials. Contraception 2001;63:297-302. (Pubitemid 32970785)
41. Thiboutot D, Archer DF, Lemay A, et al. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril 2001;76:461-8.
42. Sibai BM, Odlind V, Meador ML, et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002;77:S19-26. (Pubitemid 34155401)
43. Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: Effects on weight. Cochrane Database Syst Rev 2008:CD003987.
44. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21.
45. Endrikat J, Sandri M, Gerlinger C, et al. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight. Eur J Contracept Reprod Health Care 2007;12:220-8. (Pubitemid 47347173)
46. Ågren UM, Anttila M, Mäenpää -Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 ǎ -oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care 2011;16:444-57.
47. Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17b-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function. Eur J Contracept Reprod Health Care 2011;16:458-67.